Swedbank AB Reduces Holdings in Solventum Corporation $SOLV

Swedbank AB decreased its stake in shares of Solventum Corporation (NYSE:SOLV) by 19.1% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 36,908 shares of the company’s stock after selling 8,736 shares during the quarter. Swedbank AB’s holdings in Solventum were worth $2,694,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Sumitomo Mitsui DS Asset Management Company Ltd increased its position in Solventum by 0.7% during the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,778 shares of the company’s stock worth $1,500,000 after purchasing an additional 140 shares in the last quarter. CHICAGO TRUST Co NA boosted its stake in shares of Solventum by 3.0% during the 3rd quarter. CHICAGO TRUST Co NA now owns 5,188 shares of the company’s stock worth $379,000 after purchasing an additional 150 shares during the last quarter. Applied Finance Capital Management LLC grew its holdings in shares of Solventum by 3.8% during the second quarter. Applied Finance Capital Management LLC now owns 4,428 shares of the company’s stock worth $336,000 after buying an additional 162 shares in the last quarter. Lazard Asset Management LLC raised its position in shares of Solventum by 1.4% in the second quarter. Lazard Asset Management LLC now owns 11,605 shares of the company’s stock valued at $880,000 after buying an additional 163 shares during the last quarter. Finally, Orion Porfolio Solutions LLC raised its position in shares of Solventum by 0.7% in the second quarter. Orion Porfolio Solutions LLC now owns 24,295 shares of the company’s stock valued at $1,843,000 after buying an additional 176 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. UBS Group reiterated a “neutral” rating on shares of Solventum in a report on Friday, November 21st. Wall Street Zen upgraded Solventum from a “hold” rating to a “buy” rating in a research note on Saturday, December 13th. Weiss Ratings reiterated a “hold (c)” rating on shares of Solventum in a research report on Thursday, October 30th. Jefferies Financial Group started coverage on Solventum in a report on Thursday, September 11th. They issued a “hold” rating and a $80.00 price target for the company. Finally, BTIG Research raised shares of Solventum from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a research note on Tuesday, December 2nd. Four analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Solventum currently has a consensus rating of “Hold” and an average price target of $87.00.

Solventum Trading Up 0.3%

Shares of SOLV opened at $80.45 on Friday. Solventum Corporation has a 12 month low of $60.70 and a 12 month high of $88.20. The stock’s 50-day moving average is $77.73 and its two-hundred day moving average is $74.86. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.50 and a quick ratio of 1.14. The stock has a market cap of $13.95 billion, a PE ratio of 9.27, a P/E/G ratio of 8.49 and a beta of 0.26.

Solventum (NYSE:SOLV) last posted its earnings results on Thursday, November 6th. The company reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.43 by $0.07. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The business had revenue of $2.10 billion for the quarter, compared to analysts’ expectations of $2.05 billion. During the same period in the previous year, the company posted $1.64 earnings per share. The business’s revenue for the quarter was up .7% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. Equities analysts forecast that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Solventum announced that its Board of Directors has initiated a stock buyback plan on Thursday, November 20th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the company to buy up to 7.5% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s leadership believes its stock is undervalued.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.